Gamifant Patient Services
833.597.6530
Gamifant® (emapalumab-lzsg) is the first and only FDA-approved treatment for patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
Starting my primary HLH journey Learn about the disease, symptoms, and treatment options
Already taking or considering Gamifant See if Gamifant is the right treatment option for you or your child
Looking for support and guidance Find other resources and support networks that could be helpful
This website is intended for US healthcare providers. By continuing, you confirm you are a healthcare provider.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.